SAMRAT PHARMACHEM LTD.
Latest filings
Next results: Sat, 14 Nov · Financial Results- Reg 74(5) certificate submitted for quarter ended September 2026 · Compliance
- Board meeting on Nov 14 to consider Q2 FY27 results · Results
- Trading window closed from October 1, 2026 till 48 hours after Q2 results · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures iodine derivatives that it sells to customers in the pharmaceutical, FMCG, animal feed and agrochemical industries, a business it has run for about 30 years. Revenue for FY26 was ₹28,972.12 lakhs, up 1.35% year-on-year, but the company swung to a net loss of ₹331.20 lakhs from a ₹711.22 lakh profit in FY25. The cost of materials consumed climbed to ₹28,966.68 lakhs — shown as 100% of revenue — while employee cost was 0.8% of revenue, other operating expenses 2.3%, depreciation 0.2% and capex 1.1% of revenue. Quarterly revenue was uneven, with Q3 FY26 at ₹6,342.61 lakhs down roughly 20% from the prior quarter. The company has ₹30 crore of bank facilities rated by CRISIL, which downgraded the long-term rating to BB+/Negative in December 2025 citing volatile iodine prices and forex. Cash from operations was positive at ₹887.99 lakhs in FY26 and the balance sheet carried no long-term debt.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SAMRAT PHARMACHEM LTD.'s filed financials and exchange disclosures
What does SAMRAT PHARMACHEM LTD. do?
SAMRAT PHARMACHEM LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is SAMRAT PHARMACHEM LTD. profitable?
No. Over the trailing twelve months SAMRAT PHARMACHEM LTD. reported a net loss of ₹2.21 Cr on revenue of ₹294 Cr.
Does SAMRAT PHARMACHEM LTD. pay a dividend?
Yes. The dividend yield is 0.38% at the current price.
Is SAMRAT PHARMACHEM LTD. debt-free?
No. It reported borrowings of ₹11 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹4.82 Cr after cash. Debt stands at 0.16× equity. That is higher than 51% of its 166 Pharmaceuticals peers.
How much does the SAMRAT PHARMACHEM LTD. share price move in a day?
On a typical session SAMRAT PHARMACHEM LTD. moves 1.75% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are SAMRAT PHARMACHEM LTD.'s next results?
Financial Results on Sat, 14 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track SAMRAT PHARMACHEM LTD.'s announcements?
Every NSE and BSE filing by SAMRAT PHARMACHEM LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.